IXICO plc announced that it has signed a contract with the Global Alzheimer's Platform Foundation (GAP) to support GAP's planned Bio-Hermes 2 trial. The contract value is worth over £1 million over a 48-month term. The Company does not expect to adjust its expectations of performance for the financial year ending 30 September 2024 (FY24) following the receipt of this contract.

In the Bio-Hermes 2 trial, IXICO will apply its expertise to qualify approximately 30 participating imaging centres for the collection of amyloid PET and tau PET molecular imaging and MR Imaging scans from approximately 1,200 volunteers over the age of 60. The volunteers will be screened for Preclinical Alzheimer's Disease, Prodromal AD, or Mild Dementia AD, with IXICO providing both visual read and AI driven quantitative analysis across all three imaging modalities used in the Bio-Hermes 2 trial.